Literature DB >> 8611382

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.

S Brugnatelli1, A Riccardi, G Ucci, O Mora, L Barbarano, N Piva, L Piccinini, C Bergonzi, A De Paoli, M Di Stasi, E Rinaldi, G Trotti, M Petrini, E Ascari.   

Abstract

In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-alpha2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8611382      PMCID： PMC2074366          DOI： 10.1038/bjc.1996.138

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  21 in total

1.  High-dose glucocorticoid treatment of resistant myeloma.

Authors:  R Alexanian; B Barlogie; D Dixon
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

2.  Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft.

Authors:  J P Fermand; Y Levy; J Gerota; M Benbunan; J M Cosset; S Castaigne; M Seligmann; J C Brouet
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

3.  Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.

Authors:  B Steinke; F W Busch; C Becherer; P Ostendorf; H D Waller
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.

Authors:  B Barlogie; R Hall; A Zander; K Dicke; R Alexanian
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

Review 5.  Management of refractory myeloma: a review.

Authors:  A C Buzaid; B G Durie
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

6.  Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma.

Authors:  L J Brandes; L G Israels
Journal:  Eur J Haematol       Date:  1987-10       Impact factor: 2.997

7.  Biology and therapy of multiple myeloma.

Authors:  B Barlogie; R Alexanian
Journal:  Acta Haematol       Date:  1987       Impact factor: 2.195

8.  High-dose dexamethasone for refractory or relapsing multiple myeloma.

Authors:  W R Friedenberg; R A Kyle; W H Knospe; J M Bennett; A A Tsiatis; M M Oken
Journal:  Am J Hematol       Date:  1991-03       Impact factor: 10.047

9.  Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.

Authors:  G V Forgeson; P Selby; S Lakhani; G Zulian; C Viner; J Maitland; T J McElwain
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; G Ucci; R Luoni; S Brugnatelli; O Mora; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; F Alberio
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640
View more
  1 in total

1.  Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; O Mora; S Brugnatelli; C Tinelli; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; C Bergonzi; M Giordano; C Delfini; G Nicoletti; E Rinaldi; L Piccinini; D Valentini; E Ascari
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.